PEN reports Q1 2026 results on May 7 with options traders at their most defensive in a full year — even as short sellers quietly pull back from the stock.
The options signal is the sharpest positioning tell heading into the print. The put/call ratio has climbed to 1.21, its highest reading of the past 52 weeks, and runs well above its 20-day average of 1.09 — a z-score of 1.3 standard deviations above normal. That's a meaningful tilt toward downside protection for a stock trading at $325.33, down around 1% on the month. The RSI sits at 38, near oversold territory, reinforcing the sense that sentiment has cooled considerably in recent weeks.
Short interest, however, tells a different story — and the contrast matters. Bears have been covering, not piling in. SI dropped 17% over the past week to 5.4% of the free float, reversing a build through mid-April that briefly pushed it toward 6.5%. The borrow market is relaxed: cost to borrow is running at just 0.76% annualised, and availability at the current SI level is ample. There's no squeeze pressure here — the short community appears to be de-risking ahead of the number rather than pressing a thesis.
The analyst community has been broadly cautious since January, when a wave of downgrades hit on the same day — Citi, Baird, BTIG, Leerink, Truist, Jefferies, and Needham all moved to neutral-equivalent ratings simultaneously. Evercore ISI raised its target to $360 after the February print, but the consensus mean at $366 implies about 12% upside from current levels against a PE near 59x and EV/EBITDA above 38x. That's a premium valuation where execution carries extra weight. The bull case centres on mid-to-high-teens revenue growth, margin expansion, and low penetration in vascular intervention markets. Bears point to competition intensifying in mechanical thrombectomy, reimbursement risk, and integration execution. Insider activity over the past 90 days has been entirely on the sell side — CFO Maggie Yuen among those trimming — though the volumes are small relative to the company's float and appear routine rather than emphatic.
Past earnings reactions have been uneven. The November 2025 print drove a 12.6% one-day surge and nearly 19% over five days. The two most recent events, by contrast, produced almost no movement. That pattern means the market has seen both explosive and muted reactions in quick succession — the May 7 report will test whether the company's growth narrative can re-engage a Street that has spent the past four months largely moving to the sidelines.
See the live data behind this article on ORTEX.
Open PEN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
